---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-021927"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T10:51:29.071035+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO reports Q2 2023 net loss of $19.6M; receives $90M milestone from Pfizer for NGENLA approval

## Summary
- Consolidated revenue $265.4M, down from $309.9M YoY; operating income $7.0M vs loss of $10.7M.
- Pharma segment revenue rose to $43.5M; $94.9M IP transfer revenue included $90M NGENLA milestone.
- Diagnostics revenue fell to $127.0M from $186.8M due to lower COVID-19 testing volume and reimbursement.
- Cash and equivalents $108.1M, excluding the $90M milestone payment expected in August 2023.
- NGENLA approved in 44 markets; profit sharing with Pfizer begins from August 2023.

## SEC filing metadata
- accession: 0001437749-23-021927
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774923021927/0001437749-23-021927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774923021927/opk20230712_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-021927
- JSON: https://secwatch.observer/filing/0001437749-23-021927.json
- Plain text: https://secwatch.observer/filing/0001437749-23-021927.txt

## Key facts
- Earnings Releases
  OPKO HEALTH, INC. reported the quarter ended June 30, 2023 results: revenue $265.4 million, net income $19.6 million, or $0.03 per share, EPS $0.03 per share.
  - Period: the quarter ended June 30, 2023
  - Revenue: $265.4 million
  - Net income: $19.6 million, or $0.03 per share
  - EPS: $0.03 per share
  - Result: reported results
  source text: BioReference continues to implement cost-reduction initiatives as it works toward profitability. ● Consolidated: Consolidated total revenues for the second quarter of 2023 were $265.4 million compared with $309.9 million for the comparable period of 2022. Operating income for the second quarter of 2023 was $7.0 million compared with an operating loss of $10.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000143774923021927/0001437749-23-021927-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.